Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Provence Technologies Launches New USD 1.7 Million Research Programme

Published: Tuesday, January 29, 2013
Last Updated: Monday, January 28, 2013
Bookmark and Share
Screening 1000, the research project conducted by Provence Technologies, is set up to find and market a new ultra-pure molecule.

Provence Technologies has announced the launch of Screening 1000, a new USD 1.7 million (EUR 1.3 million) research programme with the goal of discovering a new ultra-pure molecule for the healthcare market.

The project is being launched by the R&D department of Provence Technologies and is being co-financed equally by Oseo, the French innovation promotion agency and Provence Technologies.

The programme is planned to run for two years and aims to develop a new range of products.

Screening 1000 will firstly analyze 1000 chemical compounds already on the market and detect those that show anomalies in purity. The use of already known compounds allows an existing range to be optimized, thereby reducing development costs.

Provence Technologies will then focus on new compounds with the most promising market potential. To help achieve this, the company will develop new approaches to purification and synthesis, making it possible to meet the purity levels required by health regulations.

“We hope this research project will create as much success as Provence Technologies enjoyed with our efforts around methylene blue. The really innovative part of this program is implementing new solutions in the fields of purification of active principles or alternative synthesis pathways,” said Claude Monteils, internal R&D project coordinator, Provence Technologies.

Monteils continued, “We are delighted that the French innovation promotion agency Oseo, which is a traditional partner of Provence Technologies, is joining us in this highly promising project and again supporting us in our strategy of innovation.”

“As well as providing R&D services in the field of fine chemistry, Provence Technologies will continue to develop its own internal research projects and proprietary research efforts,” said Dr Babak Sayah, chief operating officer, Provence Technologies.

Dr Sayah continued, “This new programme demonstrates the high added value of our own technologies in finding new uses for molecules, both old and new, in response to increasingly high stakes in public health.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!